OBJECTIVES: Liposomes sterically stabilised with polyethylene glycol (PEG) labelled with technetium-99m were tested for their ability to image adjuvant arthritis in a rat model. METHODS: Adjuvant arthritis was induced in the ankle joint of the left hind foot by injection of Mycobacterium butyricum in Freund's incomplete adjuvant in the foot pad. Seven days later animals received the following radiopharmaceuticals labelled with 99mTc (a) non-PEG-liposomes, (b) PEG-liposomes or (c) non-specific human polyclonal IgG. For each of the radiopharmaceuticals the in vivo distribution of the radiolabel was monitored both scintigraphically as well as by counting the dissected tissues at two, eight, and 24 hours after injection. RESULTS: The pharmacokinetics of the radiopharmaceuticals differed considerably (halflife in the blood: PEG-liposomes (18 hours) > 99mTc-IgG (3 hours) > non-PEG liposomes (1 hour)). The inflamed focus was visualised with each of the agents. The uptake of each of the radiopharmaceuticals in the inflamed ankle region correlated with their residence time in the blood (inflamed joint uptake: PEG liposomes (1.15% injected dose (ID)/ g) > 99mTc-IgG (0.35% ID/g) > non-PEG-liposomes (0.05% ID/g)). Quantitative analysis of the images showed that the inflamed ankle to background ratio was highest with the PEG-liposomes (7.5 at 24 hours after injection), while with the other two agents this ratio did not exceed 4. CONCLUSION: This study shows that 99mTc-labelled PEG-liposomes may be an excellent agent to visualise arthritis. Increased label uptake in the inflamed joint and increased target to background ratios can be obtained with PEG-liposomes because of their long circulating properties. In addition to their use as vehicles for scintigraphic imaging of arthritis PEG-liposomes might also be used for the site specific delivery of antirheumatic drugs.
OBJECTIVES: Liposomes sterically stabilised with polyethylene glycol (PEG) labelled with technetium-99m were tested for their ability to image adjuvant arthritis in a rat model. METHODS:Adjuvant arthritis was induced in the ankle joint of the left hind foot by injection of Mycobacterium butyricum in Freund's incomplete adjuvant in the foot pad. Seven days later animals received the following radiopharmaceuticals labelled with 99mTc (a) non-PEG-liposomes, (b) PEG-liposomes or (c) non-specific human polyclonal IgG. For each of the radiopharmaceuticals the in vivo distribution of the radiolabel was monitored both scintigraphically as well as by counting the dissected tissues at two, eight, and 24 hours after injection. RESULTS: The pharmacokinetics of the radiopharmaceuticals differed considerably (halflife in the blood: PEG-liposomes (18 hours) > 99mTc-IgG (3 hours) > non-PEG liposomes (1 hour)). The inflamed focus was visualised with each of the agents. The uptake of each of the radiopharmaceuticals in the inflamed ankle region correlated with their residence time in the blood (inflamed joint uptake: PEG liposomes (1.15% injected dose (ID)/ g) > 99mTc-IgG (0.35% ID/g) > non-PEG-liposomes (0.05% ID/g)). Quantitative analysis of the images showed that the inflamed ankle to background ratio was highest with the PEG-liposomes (7.5 at 24 hours after injection), while with the other two agents this ratio did not exceed 4. CONCLUSION: This study shows that 99mTc-labelled PEG-liposomes may be an excellent agent to visualise arthritis. Increased label uptake in the inflamed joint and increased target to background ratios can be obtained with PEG-liposomes because of their long circulating properties. In addition to their use as vehicles for scintigraphic imaging of arthritisPEG-liposomes might also be used for the site specific delivery of antirheumatic drugs.
Authors: F C Breedveld; M J van Kroonenburgh; J A Camps; H I Feitsma; H M Markusse; E K Pauwels Journal: J Nucl Med Date: 1989-12 Impact factor: 10.057
Authors: W J Oyen; O C Boerman; G Storm; L van Bloois; E B Koenders; R A Claessens; R M Perenboom; D J Crommelin; J W van der Meer; F H Corstens Journal: J Nucl Med Date: 1996-08 Impact factor: 10.057
Authors: M H de Bois; M L Westedt; J W Arndt; K S Wiarda; E A van der Velde; E K Pauwels; F C Breedveld Journal: J Rheumatol Date: 1995-08 Impact factor: 4.666
Authors: R H Rubin; A J Fischman; R J Callahan; B A Khaw; F Keech; M Ahmad; R Wilkinson; H W Strauss Journal: N Engl J Med Date: 1989-10-05 Impact factor: 91.245
Authors: M Luísa Corvo; H Susana Marinho; Paulo Marcelino; Rui M Lopes; Carlos A Vale; Claúdia R Marques; Luísa C D Martins; Peter Laverman; Gert Storm; M Bárbara A F Martins Journal: Pharm Res Date: 2014-07-19 Impact factor: 4.200
Authors: Xin-Ming Liu; Ling-Dong Quan; Jun Tian; Yazen Alnouti; Kai Fu; Geoffrey M Thiele; Dong Wang Journal: Pharm Res Date: 2008-07-23 Impact factor: 4.200